Jeffrey V. Leyton Department of Nuclear Medicine and Radiobiology Université de Sherbrooke Biography Publications Institution JoVE Articles Jeffrey V. Leyton has not added a biography. If you are Jeffrey V. Leyton and would like to personalize this page please email our Author Liaison for assistance. Publications Targeting IL-5Rα with Antibody-conjugates Reveals a Strategy for Imaging and Therapy for Invasive Bladder Cancer Oncoimmunology. 2017 | Pubmed ID: 29123949 BODIPY-17α-ethynylestradiol Conjugates: Synthesis, Fluorescence Properties and Receptor Binding Affinities Bioorganic & Medicinal Chemistry Letters. Feb, 2017 | Pubmed ID: 28049591 Paradoxical Effects of Auger Electron-emitting (111)In-DTPA-NLS-CSL360 Radioimmunoconjugates on HCD45(+) Cells in the Bone Marrow and Spleen of Leukemia-engrafted NOD/SCID or NRG Mice Nuclear Medicine and Biology. Oct, 2016 | Pubmed ID: 27497632 Development of a Novel Covalent Folate-Albumin-Photosensitizer Conjugate Photochemistry and Photobiology. 07, 2016 | Pubmed ID: 27221219 ChAcNLS, a Novel Modification to Antibody-Conjugates Permitting Target Cell-Specific Endosomal Escape, Localization to the Nucleus, and Enhanced Total Intracellular Accumulation Molecular Pharmaceutics. Jun, 2016 | Pubmed ID: 27112376 Auger Electron-emitting (111)In-DTPA-NLS-CSL360 Radioimmunoconjugates Are Cytotoxic to Human Acute Myeloid Leukemia (AML) Cells Displaying the CD123(+)/CD131(-) Phenotype of Leukemia Stem Cells Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine. Apr, 2016 | Pubmed ID: 26748017 The Human Polynucleotide Kinase/phosphatase (hPNKP) Inhibitor A12B4C3 Radiosensitizes Human Myeloid Leukemia Cells to Auger Electron-emitting Anti-CD123 ¹¹¹In-NLS-7G3 Radioimmunoconjugates Nuclear Medicine and Biology. May-Jun, 2014 | Pubmed ID: 24637100 細胞集積量の増加と腫瘍標的化の改善のためウイルス由来ペプチド修飾抗体複合体の初期評価 Simon Beaudoin1, Michel Paquette1, Laurent Fafard-Couture1, Mylene A. Tremblay1, Roger Lecomte1,2,3, Brigitte Guérin1,2,3, Jeffrey V. Leyton1,2,3 1Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 2Sherbrooke Molecular Imaging Center (CIMS), Université de Sherbrooke, 3Sherbrooke Institute of Pharmacology JoVE 55440 Bioengineering
細胞集積量の増加と腫瘍標的化の改善のためウイルス由来ペプチド修飾抗体複合体の初期評価 Simon Beaudoin1, Michel Paquette1, Laurent Fafard-Couture1, Mylene A. Tremblay1, Roger Lecomte1,2,3, Brigitte Guérin1,2,3, Jeffrey V. Leyton1,2,3 1Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, 2Sherbrooke Molecular Imaging Center (CIMS), Université de Sherbrooke, 3Sherbrooke Institute of Pharmacology JoVE 55440 Bioengineering
